Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Sep 6:5:F1000 Faculty Rev-2234.
doi: 10.12688/f1000research.8976.1. eCollection 2016.

Recent advances in understanding vitiligo

Affiliations
Review

Recent advances in understanding vitiligo

Prashiela Manga et al. F1000Res. .

Abstract

Vitiligo, an acquired depigmentation disorder, manifests as white macules on the skin and can cause significant psychological stress and stigmatization. Recent advances have shed light on key components that drive disease onset and progression as well as therapeutic approaches. Vitiligo can be triggered by stress to the melanin pigment-producing cells of the skin, the melanocytes. The triggers, which range from sunburn to mechanical trauma and chemical exposures, ultimately cause an autoimmune response that targets melanocytes, driving progressive skin depigmentation. The most significant progress in our understanding of disease etiology has been made on three fronts: (1) identifying cellular responses to stress, including antioxidant pathways and the unfolded protein response (UPR), as key players in disease onset, (2) characterizing immune responses that target melanocytes and drive disease progression, and (3) identifying major susceptibility genes. The current model for vitiligo pathogenesis postulates that oxidative stress causes cellular disruptions, including interruption of protein maturation in the endoplasmic reticulum (ER), leading to the activation of the UPR and expression of UPR-regulated chemokines such as interleukin 6 (IL-6) and IL-8. These chemokines recruit immune components to the skin, causing melanocytes to be targeted for destruction. Oxidative stress can further increase melanocyte targeting by promoting antigen presentation. Two key components of the autoimmune response that promote disease progression are the interferon (IFN)-γ/CXCL10 axis and IL-17-mediated responses. Several genome-wide association studies support a role for these pathways, with the antioxidant gene NRF2, UPR gene XBP1, and numerous immune-related genes including class I and class II major histocompatibility genes associated with a risk for developing vitiligo. Novel approaches to promote repigmentation in vitiligo are being investigated and may yield effective, long-lasting therapies.

Keywords: IFN-γ; Phototherapy; Vitiligo; melanocyte; oxidative stress.

PubMed Disclaimer

Conflict of interest statement

In the past 12 months, Seth J. Orlow has served as a board member for Almirall and a consultant for Dermira, Provectus, and Unilever. Prashiela Manga and Nada Elbuluk declare that they have no competing interests. No competing interests were disclosed. No competing interests were disclosed. No competing interests were disclosed.

References

    1. Le Poole IC, Das PK, van den Wijngaard RM, et al. : Review of the etiopathomechanism of vitiligo: a convergence theory. Exp Dermatol. 1993;2(4):145–53. 10.1111/j.1600-0625.1993.tb00023.x - DOI - PubMed
    1. Le Poole C, Boissy RE: Vitiligo. Semin Cutan Med Surg. 1997;16(1):3–14. - PubMed
    1. Parsad D, Dogra S, Kanwar AJ: Quality of life in patients with vitiligo. Health Qual Life Outcomes. 2003;1:58. 10.1186/1477-7525-1-58 - DOI - PMC - PubMed
    1. Boissy RE, Manga P: On the etiology of contact/occupational vitiligo. Pigment Cell Res. 2004;17(3):208–14. 10.1111/j.1600-0749.2004.00130.x - DOI - PubMed
    1. Ezzedine K, Lim HW, Suzuki T, et al. : Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2012;25(3):E1–13. 10.1111/j.1755-148X.2012.00997.x - DOI - PMC - PubMed